The UCLA trial is currently enrolling patients. Clinical trial compares two targeted radiation therapies for recurrent prostate cancer. New AI tool, ProCUSNet, detects prostate cancer more accurately ...

Add Yahoo as a preferred source to see more of our stories on Google. Men whose prostate cancer returns after surgery or radiation therapy may finally have a new treatment that helps them live longer.

New research suggests that men who take multivitamins after being diagnosed with prostate cancer may have a lower risk of cancer recurrence. In the overall study group, current multivitamin users ...

Patients who reported current multivitamin use had a lower risk of recurrence than patients who had never taken multivitamins. Patients with prostate cancer may have a lower risk of recurrence if they ...

Outcomes of initial vs delayed docetaxel therapy in veterans with metastatic hormone sensitive prostate cancer and high volume of disease. Evaluation of de novo oligometastatic, oligorecurrent, and ...

SAN FRANCISCO -- For patients with recurrent prostate cancer, those with a certain subtype had clinically meaningful benefits when apalutamide (Erleada) was added to salvage radiotherapy after radical ...

An experimental new treatment slows down the spread of metastatic prostate cancer, postponing the use of hormone treatment by ...

If you or a loved one are navigating the journey of prostate cancer, you know that every decision weighs heavily. You’ve likely faced surgery or initial treatments, only to encounter the fear that ...

Men with recurrent prostate cancer following surgery or radiation therapy may now have a new chance to live longer. A massive global trial has found that a combination of two medications, enzalutamide ...

COBRA: Assessment of the efficacy of 64Cu-SAR-bisPSMA using histopathology as reference standard in patients with biochemical recurrence of prostate cancer following definitive therapy. Impact of ...

Researchers at the UCLA Health Jonsson Comprehensive Cancer Center have launched a clinical trial, called ANDROMEDA, to compare two types of targeted radiation therapy for men with recurrent prostate ...